Universe Pharmaceuticals INC
UPC
$2.91
-$0.71-19.61%
NASDAQ
| 09/30/2025 | 06/30/2025 | 09/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.35M | 4.35M | 5.07M | 6.44M | 6.44M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.35M | 4.35M | 5.07M | 6.44M | 6.44M |
| Cost of Revenue | 2.78M | 2.78M | 3.72M | 4.76M | 4.76M |
| Gross Profit | 1.57M | 1.57M | 1.35M | 1.68M | 1.68M |
| SG&A Expenses | 1.58M | 1.58M | 3.02M | 2.52M | 2.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 800.00 | -5.70K | -5.70K |
| Total Operating Expenses | 4.65M | 4.65M | 8.21M | 7.31M | 7.31M |
| Operating Income | -294.60K | -294.60K | -3.14M | -870.10K | -870.10K |
| Income Before Tax | -193.70K | -193.70K | -3.20M | -6.22M | -6.22M |
| Income Tax Expenses | -- | -- | -29.20K | 332.60K | 332.60K |
| Earnings from Continuing Operations | -193.70K | -193.70K | -3.17M | -6.55M | -6.55M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -193.70K | -193.70K | -3.17M | -6.55M | -6.55M |
| EBIT | -294.60K | -294.60K | -3.14M | -870.10K | -870.10K |
| EBITDA | -170.70K | -170.70K | -3.02M | -745.60K | -745.60K |
| EPS Basic | -0.34 | -0.34 | -145.60 | -- | -- |
| Normalized Basic EPS | -0.21 | -0.21 | -91.78 | -- | -- |
| EPS Diluted | -0.34 | -0.34 | -145.60 | -- | -- |
| Normalized Diluted EPS | -0.21 | -0.21 | -91.78 | -- | -- |
| Average Basic Shares Outstanding | 563.90K | 563.90K | 21.80K | -- | -- |
| Average Diluted Shares Outstanding | 563.90K | 563.90K | 21.80K | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |